导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.26% | 2883/4773 |
| 近一周 | -2.30% | 1720/5462 |
| 近一月 | -4.40% | 2440/5421 |
| 近一季 | -8.03% | 2645/5209 |
| 近半年 | -3.24% | 2156/4920 |
| 近一年 | 0.33% | 2591/4366 |
| 近两年 | 47.41% | 1565/2954 |
| 近三年 | 28.48% | 1120/2253 |
| 成立以来 | 150.07% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.73% 3381/4961 |
12.65% 2144/5312 |
- - |
- - |
| 2025 | 20.83% 2082/4813 |
-1.00% 2527/3635 |
2.33% 1641/4076 |
19.04% 2199/4524 |
0.20% 2140/4813 |
| 2024 | 17.40% 695/3463 |
2.95% 656/2808 |
-1.26% 1008/3014 |
17.70% 1138/3129 |
-1.88% 1875/3463 |
| 2023 | -9.50% 1177/2656 |
4.51% 935/2280 |
-4.11% 1048/2385 |
-3.06% 838/2515 |
-6.84% 1942/2655 |
| 2022 | -20.27% 953/2207 |
-14.63% 980/1919 |
7.11% 530/2016 |
-14.36% 1080/2113 |
1.82% 1128/2208 |
| 2021 | -3.79% 929/1822 |
-3.24% 786/1255 |
4.27% 904/1330 |
-6.03% 895/1466 |
1.48% 916/1822 |
| 2020 | 29.46% 536/1250 |
-10.09% 752/1028 |
13.97% 579/1067 |
11.18% 472/1164 |
13.64% 345/1184 |
| 2019 | 38.21% 312/1092 |
28.23% 322/754 |
-0.20% 235/804 |
0.70% 479/850 |
7.24% 463/918 |
| 2018 | -23.88% 305/834 |
- - |
- - |
- - |
-12.45% 444/691 |
| 2017 | 23.69% 131/714 |
- - |
- - |
- - |
- - |
| 2016 | -8.59% 250/605 |
- - |
- - |
- - |
- - |
| 2015 | 8.93% 164/575 |
- - |
- - |
- - |
- - |
| 2014 | 53.49% 61/237 |
- - |
- - |
- - |
- - |
| 2013 | -5.44% 97/186 |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华夏沪深300ETF VS. 长安沪深300非周期A(740101) |